|
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …
Financial Post The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall … |
|
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …
Business Wire (press release) The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall … |
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …MarketWatch (press release)… (prolonged-release fampridine tablets). The company will also present results from the investigational trials of its late-stage MS pipeline,…
|
SymBio Announces Completion of Patient Enrollment of TREAKISYM® (SyB L …
Marketwire (press release) This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP 2. SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai. |
|
iBio adds new therapeutic antibody candidate to its pipeline
pharmabiz.com Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates. “We are pleased to further expand our antibody product candidate pipeline, particularly with an … |
|
IQWiG rejects Cell Therapeutics’ Pixuvri
PMLiVE Results from the PIX306 trial, comparing Pixuvri and Roche’s MabThera (rituximab) to a regimen of Lilly’s Gemzar (gemcitabine) and MabThera, are expected by June 2015 as part of this post-marketing follow-up. Conditional marketing authorisations are … |
 Irish Times |
New drugs give real hope to MS sufferers
Irish Times Ms Kelly’s condition is a long way removed from that of Marie Fleming and more typical of the kinds of conditions encountered by MS sufferers. Another drug which is currently part of a clinical trial in Ireland is Daclizumab made by Abbvie, an offshoot … |
|
iBio Adds New Therapeutic Antibody to Its Pipeline
PharmaLive (press release) (subscription) Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates. “We are pleased to further expand our antibody product candidate pipeline, particularly with an … |
|
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …
PR Newswire (press release) GBI Research, the leading business intelligence provider, has released its latest research, “Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion”. |
|
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market …
MarketWatch (press release) GBI Research, the leading business intelligence provider, has released its latest research, “Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion”. |